Additionally, inhibiting YBX1 results in a significant reduction in the S phase content, along with a notable decrease in CDC6 (Cell Division Cycle 6) expression in breast cancer cells [45] and chordoma cells [25]. This evidence concerns the gene YBX1 and breast carcinoma.